@entity470 ( @entity470 ) @entity4149 kinase inhibitors (TKI) have been used as a powerful targeting therapeutic agent for treatment of @entity2220 for years. Nevertheless, the efficacy of TKI was hampered by the appearance of acquired TKI-resistance. In the present study, we aimed to search, predict, and screen the agents that can overcome the acquired TKI-resistance of @entity2220 by using the expression profiles of differentially expressed genes (DEGs) and Connectivity map (CMAP). The profiles of DEGs were obtained by searching GEO microarray database, and then, they were submitted to CMAP for analysis in order to predict and screen the agent that might reverse the TKI-resistance of @entity2 cells. Next, the effects of the selected agent on TKI-resistant @entity5 cells were tested and the possible signaling pathways were also evaluated. As a result, @entity1092 ( @entity3262 ) was selected. Then, we used a low-concentration of @entity3262 that has little effect on the cell growth for analysis. Interestingly, the results showed that treatment with a combination of @entity3262 and @entity3866 significantly led to a decrease in cell viability and an increase in cell apoptosis for TKI-resistant @entity1 -ER cells, relative to those treated with @entity3262 or @entity3866 alone. Further experiments confirmed that inhibition of MAPK and AKT might be involved in this process. Analyzing the DEGs through the CMAP is a good strategy for exploitation of anti- @entity5 agents. @entity3262 might markedly increase the sensitivity of TKI-resistant @entity2220 cells to @entity3866 , thus reversing the acquired TKI-resistance of @entity5 cells and raising @entity3262 as a potential agent for TKI-resistant @entity2 therapy.

XXXX , an inhibitor of class I histone deacetylases, reverses acquired @entity3866 -resistance of @entity2220 cells: a Connectivity Mapping analysis and an experimental study.

@entity1 :: ('9606', 'Species') :: ['HCC827'] @entity3262 :: ('D014635', 'Chemical') :: ['VPA'] @entity470 :: ('1956', 'Gene') :: ['Epidermal growth factor receptor', 'EGFR'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer'] @entity1092 :: ('MESH:D014635', 'Chemical') :: ['valproic acid'] @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer'] @entity4149 :: ('D014443', 'Chemical') :: ['tyrosine'] @entity2220 :: ('MESH:C538231', 'Disease') :: ['lung adenocarcinoma'] @entity3866 :: ('MESH:C400278', 'Chemical') :: ['Erlotinib']
@entity1092 :: (MESH:D014635,Chemical) :: ['Valproic acid']
